Patents by Inventor Alexander Fraser
Alexander Fraser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240149171Abstract: A method for creating a cryptographically secured digital asset includes: a. using at least a first activity data sensor to collect data relating to an activity carried out by a user, b. transmitting the data to a processing system, c. using the processing system to generate a digital asset based on the data, and d. cryptographically securing the digital asset. A system for creating a cryptographically secured digital asset includes at least a first activity data sensor configured to collect data relating to an activity carried out by a user, and a processing system configured to receive the data from the first activity data sensor, generate a digital asset based on the data, and cryptographically secure the digital asset.Type: ApplicationFiled: March 14, 2022Publication date: May 9, 2024Inventors: Cory David PADDOCK, Julia Breanne EVERETT, Joanna Klara MAJCHERKIEWICZ, Samuel Carl William BLADES, Tyler Alexander FRASER, Jeffrey Thompson KNIGHT
-
Publication number: 20240116938Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.Type: ApplicationFiled: April 18, 2023Publication date: April 11, 2024Applicant: Cancer Research Technology LimitedInventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
-
Publication number: 20240091571Abstract: A respirator comprising: an air supply unit arranged to deliver air at its output.Type: ApplicationFiled: July 14, 2021Publication date: March 21, 2024Applicant: BAE SYSTEMS plcInventors: Michael Fraser, Paul Douglas, Alexander Grint, Anna Welch, Alan Felstead, Neville Clokey, Julie Johnston
-
Publication number: 20230339954Abstract: The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.Type: ApplicationFiled: November 22, 2022Publication date: October 26, 2023Applicant: Cancer Research Technology LimitedInventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
-
Patent number: 11661423Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.Type: GrantFiled: October 20, 2020Date of Patent: May 30, 2023Assignee: Cancer Research Technology LimitedInventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
-
Patent number: 11634406Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.Type: GrantFiled: September 24, 2020Date of Patent: April 25, 2023Assignee: RESPIVERT LTD.Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
-
Patent number: 11548896Abstract: The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.Type: GrantFiled: February 2, 2021Date of Patent: January 10, 2023Assignee: Cancer Research Technology LimitedInventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
-
Patent number: 11142515Abstract: There are provided compounds of formula (I) as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.Type: GrantFiled: March 27, 2019Date of Patent: October 12, 2021Assignee: Respivert LimitedInventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Diane Venable, Iain Walters
-
Publication number: 20210179584Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.Type: ApplicationFiled: September 24, 2020Publication date: June 17, 2021Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
-
Publication number: 20210155628Abstract: The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.Type: ApplicationFiled: February 2, 2021Publication date: May 27, 2021Inventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
-
Patent number: 10954241Abstract: The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.Type: GrantFiled: April 18, 2017Date of Patent: March 23, 2021Assignee: Cancer Research Technology LimitedInventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
-
Publication number: 20210047334Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.Type: ApplicationFiled: October 20, 2020Publication date: February 18, 2021Applicant: Cancer Research Technology LimitedInventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
-
Patent number: 10844067Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.Type: GrantFiled: April 18, 2017Date of Patent: November 24, 2020Assignee: Cancer Research Technology LimitedInventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
-
Patent number: 10815217Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.Type: GrantFiled: July 11, 2018Date of Patent: October 27, 2020Assignee: Respivert Ltd.Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
-
Patent number: 10626126Abstract: There are provided 5,6-dihydro-4H-dithieno[3,2-b:2?,3?-d]azepine derivatives(as defined in the disclosure) which are useful in the treatment of RSV infection and for the prevention of disease associated with RSV infection.Type: GrantFiled: April 7, 2017Date of Patent: April 21, 2020Assignee: PULMOCIDE LIMITEDInventors: Simon Fraser Hunt, Stuart Thomas Onions, Vladimir Sherbukhin, Euan Alexander Fraser Fordyce, Jennifer Claire Thomas, Peter John Murray, Matthew Stephen Coates, Daniel William Brookes, Kazuhiro Ito, Peter Strong
-
Publication number: 20200002311Abstract: There are provided compounds of formula (I) as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.Type: ApplicationFiled: March 27, 2019Publication date: January 2, 2020Inventors: Alistair Ian LONGSHAW, Euan Alexander Fraser FORDYCE, Stuart Thomas ONIONS, John KING-UNDERWOOD, Jennifer Diane VENABLE, lain WALTERS
-
Patent number: 10472375Abstract: There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative which is useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection. (Formula (I)).Type: GrantFiled: March 11, 2019Date of Patent: November 12, 2019Assignee: PULMOCIDE LIMITEDInventors: Simon Fraser Hunt, Stuart Thomas Onions, Vladimir Sherbukhin, Euan Alexander Fraser Fordyce, Peter John Murray, Daniel William Brookes, Kazuhiro Ito, Peter Strong, Matthew Stephen Coates
-
Publication number: 20190263819Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.Type: ApplicationFiled: April 18, 2017Publication date: August 29, 2019Inventors: Allan Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
-
Publication number: 20190202841Abstract: There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative which is useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection. (Formula (I)).Type: ApplicationFiled: March 11, 2019Publication date: July 4, 2019Inventors: Simon Fraser Hunt, Stuart Thomas Onions, Vladimir Sherbukhin, Euan Alexander Fraser Fordyce, Peter John Murray, Daniel William Brookes, Kazuhiro ITO, Peter Strong, Matthew Stephen Coates
-
Patent number: 10294216Abstract: There are provided compounds of formula (I) shown below as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.Type: GrantFiled: December 21, 2017Date of Patent: May 21, 2019Assignee: RESPIVERT LIMITEDInventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Diane Venable, Iain Walters